Beyond weight loss, GLP-1s may offer a "two-for-one" benefit by protecting heart health, which is the leading cause of ...

Therapy for HR-positive/HER2-negative breast cancer therapy has multiple parts, depending on your specific treatment plan: Two common treatments are endocrine ...

The phase 3 PADMA trial demonstrated that first-line treatment with palbociclib plus endocrine therapy (ET) significantly improves outcomes compared with standard mono chemotherapy in patients with ...

Aligning hormone treatment administration with the body’s natural circadian rhythms could enhance efficacy, reduce adverse effects, and even cut down on the need for multiple daily doses, emerging ...

Women with breast cancer treated with complementary and alternative medicines have significantly worse survival than those receiving traditional therapies, likely due to underutilization of proven ...

Don't blame a menopause fad. There is little incentive for pharmacy companies to ensure smooth, consistent access.